Results 81 to 90 of about 19,560 (233)

Pharmacokinetics of intravitreal bevacizumab (Avastin®) in rabbits

Clinical Ophthalmology, 2011
To describe the pharmacokinetics of intravitreal bevacizumab (Avastin®) in rabbits.The right eye of 20 rabbits was injected intravitreally with 1.25 mg/0.05 mL bevacizumab. Both eyes of four rabbits each time were enucleated at days 1, 3, 8, 15, and 29. Bevacizumab concentrations were measured in serum, aqueous humor, and vitreous.Maximum vitreous (406.
Sinapis, C.I., Routsias, J.G., Sinapis, A.I., Sinapis, D.I., Agrogiannis, G.D., Pantopoulou, A., Theocharis, S.E., Baltatzis, S., Patsouris, E., Perrea, D.   +9 more
openaire   +5 more sources

Nanostructured drug delivery systems for posterior segment eye diseases: Strategies to defy ocular barriers

BMEMat, Volume 4, Issue 1, March 2026.
Efficient drug delivery to the posterior segment of the eye has long been a challenging issue due to the complex ocular barriers. The review focuses on the promise held by nanoplatforms for barrier penetration and the key mechanisms involved, also highlighting their advantages in achieving efficient drug delivery and superior treatment of PSEDs ...
Yifan Shen, Ying Yao, Yan Zhang, Xinyu Shi, Ling Bai, Yang Zhong, Yan Zhang, Kun Zhang   +7 more
wiley   +1 more source

Acute anterior uveitis following intravitreal bevacizumab but not subsequent ranibizumab

Clinical Ophthalmology, 2011
Christina Antonopoulos1, Maxwell Stem2, Grant M Comer21Department of Ophthalmology, Boston University, Boston, MA, USA; 2WK Kellogg Eye Center, Department of Ophthalmology, University of Michigan, Ann Arbor, MI, USAPurpose: Previous reports have ...
Antonopoulos C, Stem M, Comer GM
doaj  

Adverse skin reactions following intravitreal bevacizumab injection [PDF]

BMJ Case Reports, 2011
The authors describe two separate cases of skin eruption following intravitreal bevacizumab injection with evidence to suggest that these were adverse drug reactions to bevacizumab. The authors also discuss how each case was treated and report on the final outcome.
S, Ameen, M, Entabi, N, Lee, A, Stavrakoglou   +3 more
openaire   +2 more sources

Renal‐Limited Thrombotic Microangiopathy due to Anti‐VEGF/TKI Immunotherapy for Metastatic Renal Cell Carcinoma Presenting as Nephrotic Syndrome: A Case Report and Literature Review

Clinical Case Reports, Volume 14, Issue 3, March 2026.
ABSTRACT Vascular endothelial growth factor (VEGF) inhibition may result in proteinuria, worsening hypertension, chronic kidney injury, or glomerular disease. Recently, systemic VEGF inhibition has been reported to cause nephrotic disorders and thrombotic microangiopathy (TMA).
Sundus Sardar, Ahmad Matarneh, Omar K. Salameh, Abdel‐Rauof M. Akkari, Monika Joshi, Erik Washburn, Nasrollah Ghahramani, Naman Trivedi   +7 more
wiley   +1 more source

Intravitreal bevacizumab for delayed radiation maculopathy and papillopathy after irradiation for maxillary sinus cancer

Clinical Ophthalmology, 2011
Miki Gondo1, Tsutomu Sakai1, Hiroshi Tsuneoka1, Chihiro Kanehira21Department of Ophthalmology, Jikei University School of Medicine, 2Division of Radiology, Jikei University School of Medicine, Tokyo, JapanBackground: The evaluation of intravitreal ...
Gondo M, Sakai T, Tsuneoka H, Kanehira C
doaj  

Ranibizumab e bevacizumab intravítreo no tratamento da neovascularização de coróide extrafoveal da degeneração macular relacionada à idade [PDF]

, 2009
PURPOSE: To investigate the efficacy of vascular endothelial growth factor-specific (VEGF) monoclonal antibodies in the treatment of choroidal neovascularization secondary to age-related macular degeneration (AMD) that does not extend beneath the foveal ...
Amaro, Miguel Hage, Roller, Aaron Brock
core   +3 more sources

Intravitreal bevacizumab for macular telangiectasia

Acta Ophthalmologica, 2010
Abstract Purpose Idiopathic macular telangiectasia Type 2 (idiopathic perifoveolar telangiectasia, ITP) is an uncommon, slowly progressive, usually bilateral disease of the macula, characterized by dilated, tortuous capillaries in the perifoveolar region, preferably in the temporal part. It is the scope of our study to report about a 36 month follow‐up
T LIBONDI, S VON BALTZ, JB JONAS
openaire   +1 more source

Current and Emerging Pharmacologic Therapies for Diabetic Retinopathy

Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, Volume 46, Issue 3, March 2026.
ABSTRACT Diabetic retinopathy, a prevalent microvascular complication of diabetes mellitus, is a leading cause of blindness among adults in developed countries. Risk factors include prolonged duration of diabetes, elevated glycosylated hemoglobin levels, hypertension, and dyslipidemia, with rapid glucose reduction also increasing risk for developing ...
Jennifer N. Clements, Julia Mesawich, Cassandra Twisdale   +2 more
wiley   +1 more source

Intravitreal injection of Ozurdex(®) implant in patients with persistent diabetic macular edema, with six-month follow-up [PDF]

, 2016
AIM: To evaluate the efficacy of intravitreal dexamethasone injections in diabetic macular edema (DME). METHODS: A 700 μg slow-release intravitreal dexamethasone implant (Ozurdex®) was placed in the vitreal cavity of 17 patients (19 eyes) affected ...
Bottone, A, FAMELI, VALERIA, Ferraresi, AF, Giustolisi, R, Lenzi, T, PACELLA, Elena, Pacella, F, Romano, MR, Turchetti, P   +8 more
core   +2 more sources